The plant located at Dahej SEZ, in Gujarat, has also received approval from EU Germany Torrent Pharma said its third manufacturing plant in Gujarat has obtained the Establishment Inspection Report (EIR) from the US health reg
Aurobindo Pharma has received final approval from the USFDA to manufacture and market its Tranexamic acid injection, used for treating hemophilia, in the American market. The company plans to launch the product by the end of
The letters were received for its two facilities in Gujarat Cadila Healthcare has received a warning letter from the US Food and Drug Administration (US FDA) for its two facilities in Gujarat. “The company has received
Last month, the country's second-largest drug maker, Dr Reddy's, had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.
Drug major Sun Pharmaceutical has withdrawn its appeal in the lawsuit filed by Ranbaxy against the US health regulator challenging FDA's decision to revoke approvals for generic versions of Nexium and Valcyte.
Jubilant Life Sciences shares gained as much as 3.5 per cent intraday on Wednesday after the company informed BSE that it has received approval from the US health regulator to market Indomethacin capsule used for treating pai
The drug targets hard-to-treat colorectal and pancreatic cancers, but may also prove suitable to treat breast, lung and other tumours A new class of drug that reduces cancer recurrence and spread may soon be available, with S
Aurobindo Pharma shares over 3 per cent in the early trade on Monday on BSE after the company on August 29 said it has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Ralox
Dr Reddy's Laboratories has started recalling Divalproex Sodium extended-release tablets as it has failed dissolution tests, and Amlodipine Besylate and Atorvastatin Calcium tablets since these are close to expiry time.
Product to be launched immediately Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine tablets USP, 150 mg/300 mg. According to IMS data, the US ma